Open Questions: Clinical

Ranked research questions extracted from wiki pages and knowledge gaps
Field: GenesProteinsMechanismsTherapeuticsDiseasesPathwaysCell TypesBrain RegionsMethods
Sort by: Importance Elo Potential Impact Tractability
200 questions found for field 'Clinical'
open ⚖ 1500
API Generation AD:
📑 0.50 💥 0.50
open ⚖ 1500
DIAN-TU-EXR:
📑 0.50 💥 0.50
open ⚖ 1500
Are effects disease-modifying or purely symptomatic?
📑 0.50 💥 0.50
open ⚖ 1500
Long-term durability of benefits?
📑 0.50 💥 0.50
open ⚖ 1500
Home-based systems
📑 0.50 💥 0.50
open ⚖ 1500
Combination with other neuromodulation
📑 0.50 💥 0.50
open ⚖ 1500
Microbiome modulation
📑 0.50 💥 0.50
open ⚖ 1500
Multi-target stimulation
📑 0.50 💥 0.50
open ⚖ 1500
Small molecule priming
📑 0.50 💥 0.50
open ⚖ 1500
With small molecules
📑 0.50 💥 0.50
open ⚖ 1500
With rehabilitation
📑 0.50 💥 0.50
open ⚖ 1500
With devices
📑 0.50 💥 0.50
open ⚖ 1500
VR + Gene Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Selection
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal Changes
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Companion Diagnostics
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Other tauopathies
📑 0.50 💥 0.50
open ⚖ 1500
Optimal Imaging Protocols
📑 0.50 💥 0.50
open ⚖ 1500
Quantitative Metrics
📑 0.50 💥 0.50
open ⚖ 1500
Genetic risk scores
📑 0.50 💥 0.50
open ⚖ 1500
Digital biomarkers
📑 0.50 💥 0.50
open ⚖ 1500
Other neurodegenerative conditions
📑 0.50 💥 0.50
open ⚖ 1500
Systemic inflammatory conditions
📑 0.50 💥 0.50
open ⚖ 1500
P. gingivalis testing
📑 0.50 💥 0.50
open ⚖ 1500
Gingipain activity
📑 0.50 💥 0.50
open ⚖ 1500
Closed-loop systems
📑 0.50 💥 0.50
open ⚖ 1500
Multi-frequency stimulation
📑 0.50 💥 0.50
open ⚖ 1500
Expanded Trials:
📑 0.50 💥 0.50
open ⚖ 1500
Frontotemporal dementia
📑 0.50 💥 0.50
open ⚖ 1500
Primary prevention:
📑 0.50 💥 0.50
open ⚖ 1500
Compare to standard-of-care
📑 0.50 💥 0.50
open ⚖ 1500
Registration Trial
📑 0.50 💥 0.50
open ⚖ 1500
Patient Population
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-Driven
📑 0.50 💥 0.50
open ⚖ 1500
Feasibility
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Personalized protocols
📑 0.50 💥 0.50
open ⚖ 1500
Integration with wearable sensors
📑 0.50 💥 0.50
open ⚖ 1500
Large-scale trials
📑 0.50 💥 0.50
open ⚖ 1500
Potential expansion
📑 0.50 💥 0.50
open ⚖ 1500
Combination potential
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Combination trials
📑 0.50 💥 0.50
open ⚖ 1500
Novel IL-2 formulations
📑 0.50 💥 0.50
open ⚖ 1500
Adaptive trials
📑 0.50 💥 0.50
open ⚖ 1500
Alternative targets
📑 0.50 💥 0.50
open ⚖ 1500
Cell therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker expansion
📑 0.50 💥 0.50
open ⚖ 1500
AI integration
📑 0.50 💥 0.50
open ⚖ 1500
Directional leads
📑 0.50 💥 0.50
open ⚖ 1500
Chronic sensing
📑 0.50 💥 0.50
open ⚖ 1500
Gene-modified cells
📑 0.50 💥 0.50
open ⚖ 1500
Scaffold-based delivery
📑 0.50 💥 0.50
open ⚖ 1500
Exosome therapeutics
📑 0.50 💥 0.50
open ⚖ 1500
Patient-specific iPSC lines
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker-guided selection
📑 0.50 💥 0.50
open ⚖ 1500
Dosing optimization
📑 0.50 💥 0.50
open ⚖ 1500
Platform trials
📑 0.50 💥 0.50
open ⚖ 1500
Real-world evidence
📑 0.50 💥 0.50
open ⚖ 1500
Sample Size
📑 0.50 💥 0.50
open ⚖ 1500
Longer Duration
📑 0.50 💥 0.50
open ⚖ 1500
VR + Pharmacological
📑 0.50 💥 0.50
open ⚖ 1500
VR + Stem Cells
📑 0.50 💥 0.50
open ⚖ 1500
Severity Stratification
📑 0.50 💥 0.50
open ⚖ 1500
Comorbidity Adjustment
📑 0.50 💥 0.50
open ⚖ 1500
Home vs. Facility
📑 0.50 💥 0.50
open ⚖ 1500
Broader AD indications
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Prevention trials
📑 0.50 💥 0.50
open ⚖ 1500
Other neurodegenerative conditions
📑 0.50 💥 0.50
open ⚖ 1500
Phase 2 Completion
📑 0.50 💥 0.50
open ⚖ 1500
Phase 3 Registration Trials
📑 0.50 💥 0.50
open ⚖ 1500
Prevention studies
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
ApoE genotype
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker profiles
📑 0.50 💥 0.50
open ⚖ 1500
Optimal stimulation parameters
📑 0.50 💥 0.50
open ⚖ 1500
Treatment durability
📑 0.50 💥 0.50
open ⚖ 1500
Repeat treatment
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Parkinson's disease
📑 0.50 💥 0.50
open ⚖ 1500
Vascular dementia
📑 0.50 💥 0.50
open ⚖ 1500
The infection hypothesis
📑 0.50 💥 0.50
open ⚖ 1500
International Sites
📑 0.50 💥 0.50
open ⚖ 1500
New Treatment Arms
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapies
📑 0.50 💥 0.50
open ⚖ 1500
Other conditions:
📑 0.50 💥 0.50
open ⚖ 1500
Network-specific targeting
📑 0.50 💥 0.50
open ⚖ 1500
Earlier Intervention:
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches:
📑 0.50 💥 0.50
open ⚖ 1500
Next-Generation Vectors:
📑 0.50 💥 0.50
open ⚖ 1500
Parkinson's disease depression
📑 0.50 💥 0.50
open ⚖ 1500
Vascular dementia
📑 0.50 💥 0.50
open ⚖ 1500
Amyotrophic lateral sclerosis
📑 0.50 💥 0.50
open ⚖ 1500
Sustained efficacy
📑 0.50 💥 0.50
open ⚖ 1500
Disease modification
📑 0.50 💥 0.50
open ⚖ 1500
Cognitive outcomes
📑 0.50 💥 0.50
open ⚖ 1500
Safety monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Secondary prevention:
📑 0.50 💥 0.50
open ⚖ 1500
Combination studies:
📑 0.50 💥 0.50
open ⚖ 1500
Other dementias:
📑 0.50 💥 0.50
open ⚖ 1500
Adjunctive therapy:
📑 0.50 💥 0.50
open ⚖ 1500
Expand to multiple centers
📑 0.50 💥 0.50
open ⚖ 1500
Optimize stimulation parameters
📑 0.50 💥 0.50
open ⚖ 1500
Include biomarker-enriched populations
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
DBS + Anti-amyloid
📑 0.50 💥 0.50
open ⚖ 1500
DBS + Anti-tau
📑 0.50 💥 0.50
open ⚖ 1500
DBS + Lifestyle
📑 0.50 💥 0.50
open ⚖ 1500
Multi-target DBS
📑 0.50 💥 0.50
open ⚖ 1500
With other amyloid antibodies
📑 0.50 💥 0.50
open ⚖ 1500
With tau-targeting agents
📑 0.50 💥 0.50
open ⚖ 1500
With disease-modifying approaches
📑 0.50 💥 0.50
open ⚖ 1500
Routine Clinical Use
📑 0.50 💥 0.50
open ⚖ 1500
Therapeutic Monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Combination with Amyloid Imaging
📑 0.50 💥 0.50
open ⚖ 1500
Multi-Center Standardization
📑 0.50 💥 0.50
open ⚖ 1500
Next-generation platforms
📑 0.50 💥 0.50
open ⚖ 1500
Disease-specific optimization
📑 0.50 💥 0.50
open ⚖ 1500
Delivery innovations
📑 0.50 💥 0.50
open ⚖ 1500
Safety Profile
📑 0.50 💥 0.50
open ⚖ 1500
Trial Design
📑 0.50 💥 0.50
open ⚖ 1500
Mechanistic Validation
📑 0.50 💥 0.50
open ⚖ 1500
Anti-inflammatory therapy development
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy monitoring
📑 0.50 💥 0.50
open ⚖ 1500
Well-controlled trials
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Long-term outcomes
📑 0.50 💥 0.50
open ⚖ 1500
Personalized medicine
📑 0.50 💥 0.50
open ⚖ 1500
Corticobasal Degeneration (CBD)
📑 0.50 💥 0.50
open ⚖ 1500
[Alzheimer's Disease](/diseases/alzheimers-disease)
📑 0.50 💥 0.50
open ⚖ 1500
Primary Tauopathies
📑 0.50 💥 0.50
open ⚖ 1500
Which of latrepirdine's mechanisms contributes most to efficacy?
📑 0.50 💥 0.50
open ⚖ 1500
Are there additional unrecognized mechanisms?
📑 0.50 💥 0.50
open ⚖ 1500
Precisely how does cTBS improve motor function?
📑 0.50 💥 0.50
open ⚖ 1500
Which neuroplasticity mechanisms are engaged?
📑 0.50 💥 0.50
open ⚖ 1500
Optimal stimulation parameters?
📑 0.50 💥 0.50
open ⚖ 1500
Which patients respond best?
📑 0.50 💥 0.50
open ⚖ 1500
Predictive Validity**: How well do simulator metrics predict on-road performance?
📑 0.50 💥 0.50
open ⚖ 1500
Longitudinal Tracking**: Can simulators track change over time?
📑 0.50 💥 0.50
open ⚖ 1500
Intervention Effects**: Can simulators measure treatment response?
📑 0.50 💥 0.50
open ⚖ 1500
Population Norms**: What are normal ranges by age and condition?
📑 0.50 💥 0.50
open ⚖ 1500
Telehealth**: Can remote assessment be validated?
📑 0.50 💥 0.50
open ⚖ 1500
Optimal dosing**: What is the optimal dose for efficacy while maintaining safety in PSP patients?
📑 0.50 💥 0.50
open ⚖ 1500
Clinical outcomes**: Will tau reduction translate to clinical benefit in PSP?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker correlation**: How do changes in CSF tau relate to tau PET and clinical measures in PSP?
📑 0.50 💥 0.50
open ⚖ 1500
Disease modification**: Can early intervention alter disease trajectory in PSP?
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker stratification**: Are there biomarker subgroups that respond better to therapy?
📑 0.50 💥 0.50
open ⚖ 1500
Pediatric PD
📑 0.50 💥 0.50
open ⚖ 1500
Combination studies
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker substudy
📑 0.50 💥 0.50
open ⚖ 1500
Improved CNS Penetration
📑 0.50 💥 0.50
open ⚖ 1500
Selective Targeting
📑 0.50 💥 0.50
open ⚖ 1500
Combination Therapy
📑 0.50 💥 0.50
open ⚖ 1500
Mechanism Validation
📑 0.50 💥 0.50
open ⚖ 1500
Combination Strategies
📑 0.50 💥 0.50
open ⚖ 1500
Patient Enrichment
📑 0.50 💥 0.50
open ⚖ 1500
Endpoint Selection
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker Integration
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy studies
📑 0.50 💥 0.50
open ⚖ 1500
Cognitive outcomes
📑 0.50 💥 0.50
open ⚖ 1500
Device improvements
📑 0.50 💥 0.50
open ⚖ 1500
Comparative effectiveness
📑 0.50 💥 0.50
open ⚖ 1500
Phase 1 trials
📑 0.50 💥 0.50
open ⚖ 1500
Phase 2 trials
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker studies
📑 0.50 💥 0.50
open ⚖ 1500
Combination studies
📑 0.50 💥 0.50
open ⚖ 1500
Clinical trials
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker validation
📑 0.50 💥 0.50
open ⚖ 1500
Registry development
📑 0.50 💥 0.50
open ⚖ 1500
International collaboration
📑 0.50 💥 0.50
open ⚖ 1500
Higher dose trials
📑 0.50 💥 0.50
open ⚖ 1500
Earlier intervention
📑 0.50 💥 0.50
open ⚖ 1500
Combination therapy
📑 0.50 💥 0.50
open ⚖ 1500
Biomarker development
📑 0.50 💥 0.50
open ⚖ 1500
Combination approaches
📑 0.50 💥 0.50
open ⚖ 1500
Long-term extension
📑 0.50 💥 0.50
open ⚖ 1500
Subgroup analyses
📑 0.50 💥 0.50
open ⚖ 1500
Combination Approaches
📑 0.50 💥 0.50
open ⚖ 1500
Earlier Intervention
📑 0.50 💥 0.50
open ⚖ 1500
Enhanced Brain Penetration
📑 0.50 💥 0.50
open ⚖ 1500
Personalized Medicine
📑 0.50 💥 0.50
open ⚖ 1500
Anti-amyloid antibodies
📑 0.50 💥 0.50
open ⚖ 1500
Symptomatic treatments
📑 0.50 💥 0.50
open ⚖ 1500
Other disease-modifying agents
📑 0.50 💥 0.50
open ⚖ 1500
Patient selection
📑 0.50 💥 0.50
open ⚖ 1500
Personalized dosing
📑 0.50 💥 0.50
open ⚖ 1500
Precision medicine
📑 0.50 💥 0.50
open ⚖ 1500
Preclinical AD
📑 0.50 💥 0.50
open ⚖ 1500
At-risk populations
📑 0.50 💥 0.50
open ⚖ 1500
Long-term intervention
📑 0.50 💥 0.50
open ⚖ 1500
Phase 2b/3 trials
📑 0.50 💥 0.50
open ⚖ 1500
Combination studies
📑 0.50 💥 0.50
open ⚖ 1500
AHEAD 3 (NCT05900981):
📑 0.50 💥 0.50

🌱 Cross-Pollination

Fields that illuminate Clinical through bridging wiki connections. See all cross-field connections →

Cross-pollination from Researchers 1,300 bridges →
Cross-pollination from Institutions 2,108 bridges →
Cross-pollination from Technologies 3,032 bridges →
Open Questions | Part of the SciDEX Atlas layer | API | Cross-field map